Diabetic Nephropathy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2018’, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

- The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects

- The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Antisense Therapeutics Ltd

Araim Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd ...

Antisense Therapeutics Ltd

Araim Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd

Daiichi Sankyo Co Ltd

DiaMedica Therapeutics Inc

Dimerix Bioscience Pty Ltd

GenKyoTex SA

Gilead Sciences Inc

GNI Group Ltd

Inspyr Therapeutics Inc

Ironwood Pharmaceuticals Inc

Johnson & Johnson

MediPost Co Ltd

Merck & Co Inc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

Novo Nordisk AS

Noxxon Pharma AG

Paranta Biosciences Ltd

PhytoHealth Corp

ProMetic Life Sciences Inc

Reata Pharmaceuticals Inc

Redx Pharma Plc

Regeneron Pharmaceuticals Inc

Sarfez Pharmaceuticals Inc

Serodus ASA

Teijin Pharma Ltd

Theravance Biopharma Inc

Twoxar Inc

Ube Industries Ltd

Vascular Pharmaceuticals Inc

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Diabetic Nephropathy – Overview 5

Diabetic Nephropathy – Therapeutics Development 6

Diabetic Nephropathy – Therapeutics Assessment 17

Diabetic Nephropathy ...

Table of Contents

Table of Contents 2

Introduction 4

Diabetic Nephropathy – Overview 5

Diabetic Nephropathy – Therapeutics Development 6

Diabetic Nephropathy – Therapeutics Assessment 17

Diabetic Nephropathy – Companies Involved in Therapeutics Development 27

Diabetic Nephropathy – Drug Profiles 46

Diabetic Nephropathy – Dormant Projects 220

Diabetic Nephropathy – Discontinued Products 224

Diabetic Nephropathy – Product Development Milestones 226

Appendix 236

List of Tables

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diabetic Nephropathy – Pipeline by Antisense Therapeutics Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Araim Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Astellas Pharma Inc, H2 2018

Diabetic Nephropathy – Pipeline by AstraZeneca Plc, H2 2018

Diabetic Nephropathy – Pipeline by Bayer AG, H2 2018

Diabetic Nephropathy – Pipeline by BLR Bio LLC, H2 2018

Diabetic Nephropathy – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Diabetic Nephropathy – Pipeline by Cellmid Ltd, H2 2018

Diabetic Nephropathy – Pipeline by ChemoCentryx Inc, H2 2018

Diabetic Nephropathy – Pipeline by CSL Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Diabetic Nephropathy – Pipeline by DiaMedica Therapeutics Inc, H2 2018

Diabetic Nephropathy – Pipeline by Dimerix Bioscience Pty Ltd, H2 2018

Diabetic Nephropathy – Pipeline by GenKyoTex SA, H2 2018

Diabetic Nephropathy – Pipeline by Gilead Sciences Inc, H2 2018

Diabetic Nephropathy – Pipeline by GNI Group Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Inspyr Therapeutics Inc, H2 2018

Diabetic Nephropathy – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Johnson & Johnson, H2 2018

Diabetic Nephropathy – Pipeline by MediPost Co Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Merck & Co Inc, H2 2018

Diabetic Nephropathy – Pipeline by Mesoblast Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Diabetic Nephropathy – Pipeline by Novo Nordisk AS, H2 2018

Diabetic Nephropathy – Pipeline by Noxxon Pharma AG, H2 2018

Diabetic Nephropathy – Pipeline by Paranta Biosciences Ltd, H2 2018

Diabetic Nephropathy – Pipeline by PhytoHealth Corp, H2 2018

Diabetic Nephropathy – Pipeline by ProMetic Life Sciences Inc, H2 2018

Diabetic Nephropathy – Pipeline by Reata Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Redx Pharma Plc, H2 2018

Diabetic Nephropathy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Sarfez Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Serodus ASA, H2 2018

Diabetic Nephropathy – Pipeline by Teijin Pharma Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Theravance Biopharma Inc, H2 2018

Diabetic Nephropathy – Pipeline by Twoxar Inc, H2 2018

Diabetic Nephropathy – Pipeline by Ube Industries Ltd, H2 2018

Diabetic Nephropathy – Pipeline by Vascular Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy – Pipeline by Vicore Pharma AB, H2 2018

Diabetic Nephropathy – Dormant Projects, H2 2018

Diabetic Nephropathy – Dormant Projects, H2 2018 (Contd..1), H2 2018

Diabetic Nephropathy – Dormant Projects, H2 2018 (Contd..2), H2 2018

Diabetic Nephropathy – Dormant Projects, H2 2018 (Contd..3), H2 2018

Diabetic Nephropathy – Discontinued Products, H2 2018

Diabetic Nephropathy – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports